Private Longeveron Bets On Stem Cells For Inflammation, Aging Diseases
Executive Summary
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.
You may also be interested in...
Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
Finance Watch: Ten IPOs In Three Days Raise $1.9bn
IPO Edition: Sana leads the group with a $587.5m initial public offering, while Immunocore and Bolt follow with $200m-plus IPOs. The 10 newly public companies generated a 43.3% average return on 8 Feb.
AbbVie, Calico Extend Their Collaboration On Aging
The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.